FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / A Phase 1 clinical trial of a DNA vaccine for Venezuelan equ...
Vaccine2016; 34(31); 3607-3612; doi: 10.1016/j.vaccine.2016.04.077

A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.

Abstract: Venezuelan equine encephalitis virus (VEEV), a mosquito-borne alphavirus, causes periodic epizootics in equines and is a recognized biological defense threat for humans. There are currently no FDA-licensed vaccines against VEEV. We developed a candidate DNA vaccine expressing the E3-E2-6K-E1 genes of VEEV (pWRG/VEE) and performed a Phase 1 clinical study to assess the vaccine's safety, reactogenicity, tolerability, and immunogenicity when administered by intramuscular (IM) or intradermal (ID) electroporation (EP) using the Ichor Medical Systems TriGrid™ Delivery System. Subjects in IM-EP groups received 0.5mg (N=8) or 2.0mg (N=9) of pWRG/VEE or a saline placebo (N=4) in a 1.0ml injection. Subjects in ID-EP groups received 0.08mg (N=8) or 0.3mg (N=8) of DNA or a saline placebo (N=4) in a 0.15ml injection. Subjects were monitored for a total period of 360 days. No vaccine- or device-related serious adverse events were reported. Based on the results of a subject questionnaire, the IM- and ID-EP procedures were both considered to be generally acceptable for prophylactic vaccine administration, with the acute tolerability of ID EP delivery judged to be greater than that of IM-EP delivery. All subjects (100%) in the high and low dose IM-EP groups developed detectable VEEV-neutralizing antibodies after two or three administrations of pWRG/VEE, respectively. VEEV-neutralizing antibody responses were detected in seven of eight subjects (87.5%) in the high dose and five of eight subjects (62.5%) in the low dose ID-EP groups after three vaccine administrations. There was a correlation between the DNA dose and the magnitude of the resulting VEEV-neutralizing antibody responses for both IM and ID EP delivery. These results indicate that pWRG/VEE delivered by either IM- or ID-EP is safe, tolerable, and immunogenic in humans at the evaluated dose levels. Clinicaltrials.gov registry number NCT01984983.
Published by Elsevier Ltd.
Get Full Text
Publication Date: 2016-05-17 PubMed ID: 27206386DOI: 10.1016/j.vaccine.2016.04.077Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Phase I
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • U.S. Gov't
  • Non-P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research describes a Phase 1 clinical trial that tests a DNA vaccine for the Venezuelan equine encephalitis virus, which is an infectious disease spread by mosquitoes. Injecting this vaccine through electroporation, either intramuscularly or intradermally, appears to be safe, acceptable, and capable of triggering a protective immune response.

Introduction and Background

  • The research attempts to devise a cure for Venezuelan equine encephalitis virus (VEEV), which is a mosquito-borne virus harmful to horses and can also infect humans. There are no existing licensed vaccines against this virus.
  • The researchers have developed a candidate DNA vaccine designated pWRG/VEE. This vaccine contains the E3-E2-6K-E1 genes from VEEV.

Methodology

  • The study involves a Phase 1 clinical trial with the primary objective of assessing the safety, tolerability, reactogenicity (ability to produce common, short-term side effects), and immunogenicity (ability to provoke an immune response) of the pWRG/VEE vaccine when administered by intramuscular (IM) or intradermal (ID) electroporation (EP).
  • The vaccination was carried out using the Ichor Medical Systems TriGrid™ Delivery System.
  • The researchers carefully divided subjects into different dose groups for IM and ID delivery, as well as saline placebo controls. They monitored these subjects for a period of 360 days following administration of the vaccine.

Key Findings

  • During the course of the trial, no serious side effects were reported that could be linked directly to the vaccine or the delivery device.
  • A survey among the subjects revealed that both IM and ID electroporation procedures were assessed as generally acceptable for administering the preventive vaccine. However, the tolerability of the ID-EP method was rated higher than the IM-EP method.
  • All subjects in the high and low dose IM-EP groups developed detectable antibodies that neutralize the VEEV after two or three doses of pWRG/VEE respectively. Moreover, VEEV-neutralizing antibody responses were detected in a significant proportion of the subjects in the high dose and low dose ID-EP groups as well after three injections of the vaccine.
  • There was a notable correlation between the DNA dose of the vaccine and the magnitude of the resulting VEEV-neutralizing antibody responses for both the IM- and ID-EP delivery methods.

Conclusion

  • Given the promising results, the researchers concluded that the pWRG/VEE vaccine, delivered either intramuscularly or intradermally via electroporation, proved to be safe, tolerable, and successfully induced an immune response at the evaluated dose levels.
  • The study has been registered at Clinicaltrials.gov with the registry number NCT01984983.

Cite This Article

APA
Hannaman D, Dupuy LC, Ellefsen B, Schmaljohn CS. (2016). A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation. Vaccine, 34(31), 3607-3612. https://doi.org/10.1016/j.vaccine.2016.04.077

Publication

Vaccine
ISSN: 1873-2518
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 34
Issue: 31
Pages: 3607-3612
PII: S0264-410X(16)30242-0

Researcher Affiliations

Hannaman, Drew
  • Ichor Medical Systems, Inc., San Diego, CA, USA.
Dupuy, Lesley C
  • United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.
Ellefsen, Barry
  • Ichor Medical Systems, Inc., San Diego, CA, USA.
Schmaljohn, Connie S
  • United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA. Electronic address: connie.s.schmaljohn.civ@mail.mil.

MeSH Terms

  • Adolescent
  • Adult
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • Double-Blind Method
  • Electroporation
  • Encephalitis Virus, Venezuelan Equine
  • Encephalomyelitis, Venezuelan Equine / prevention & control
  • Female
  • Humans
  • Immunogenicity, Vaccine
  • Injections, Intradermal
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Vaccines, DNA / administration & dosage
  • Vaccines, DNA / therapeutic use
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / therapeutic use
  • Young Adult

Citations

This article has been cited 32 times.
  1. Ledesma-Feliciano C, Chapman R, Hooper JW, Elma K, Zehrung D, Brennan MB, Spiegel EK. Improved DNA Vaccine Delivery with Needle-Free Injection Systems.. Vaccines (Basel) 2023 Jan 28;11(2).
    doi: 10.3390/vaccines11020280pubmed: 36851159google scholar: lookup
  2. Babaeimarzangou SS, Zaker H, Soleimannezhadbari E, Gamchi NS, Kazeminia M, Tarighi S, Seyedian H, Tsatsakis A, Spandidos DA, Margina D. Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review).. Exp Ther Med 2023 Jan;25(1):42.
    doi: 10.3892/etm.2022.11741pubmed: 36569444google scholar: lookup
  3. Smeekens JM, Kesselring JR, Frizzell H, Bagley KC, Kulis MD. Induction of food-specific IgG by Gene Gun-delivered DNA vaccines.. Front Allergy 2022;3:969337.
    doi: 10.3389/falgy.2022.969337pubmed: 36340020google scholar: lookup
  4. Mucker EM, Brocato RL, Principe LM, Kim RK, Zeng X, Smith JM, Kwilas SA, Kim S, Horton H, Caproni L, Hooper JW. SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model.. Vaccines (Basel) 2022 Jul 9;10(7).
    doi: 10.3390/vaccines10071104pubmed: 35891268google scholar: lookup
  5. Coates EE, Edupuganti S, Chen GL, Happe M, Strom L, Widge A, Florez MB, Cox JH, Gordon I, Plummer S, Ola A, Yamshchikov G, Andrews C, Curate-Ingram S, Morgan P, Nagar S, Collins MH, Bray A, Nguyen T, Stein J, Case CL, Kaltovich F, Wycuff D, Liang CJ, Carlton K, Vazquez S, Mascola JR, Ledgerwood JE. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.. Lancet Infect Dis 2022 Aug;22(8):1210-1220.
    doi: 10.1016/S1473-3099(22)00052-4pubmed: 35568049google scholar: lookup
  6. Suschak JJ, Bixler SL, Badger CV, Spik KW, Kwilas SA, Rossi FD, Twenhafel N, Adams ML, Shoemaker CJ, Spiegel E, Hooper JW. A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge.. NPJ Vaccines 2022 Apr 22;7(1):46.
    doi: 10.1038/s41541-022-00469-xpubmed: 35459271google scholar: lookup
  7. Xu Z, Patel A, Tursi NJ, Zhu X, Muthumani K, Kulp DW, Weiner DB. Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases.. Front Med Technol 2020;2:571030.
    doi: 10.3389/fmedt.2020.571030pubmed: 35047878google scholar: lookup
  8. Torres-Ruesta A, Chee RS, Ng LFP. Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.. Microorganisms 2021 Apr 22;9(5).
    doi: 10.3390/microorganisms9050899pubmed: 33922370google scholar: lookup
  9. Mara K, Dai M, Brice AM, Alexander MR, Tribolet L, Layton DS, Bean AGD. Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.. Vaccines (Basel) 2021 Jan 17;9(1).
    doi: 10.3390/vaccines9010059pubmed: 33477334google scholar: lookup
  10. Gamat-Huber M, Jeon D, Johnson LE, Moseman JE, Muralidhar A, Potluri HK, Rastogi I, Wargowski E, Zahm CD, McNeel DG. Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).. Cancers (Basel) 2020 Sep 30;12(10).
    doi: 10.3390/cancers12102831pubmed: 33008010google scholar: lookup
  11. Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects.. Vaccines (Basel) 2020 Sep 16;8(3).
    doi: 10.3390/vaccines8030534pubmed: 32947966google scholar: lookup
  12. Rossi SL, Russell-Lodrigue KE, Plante KS, Bergren NA, Gorchakov R, Roy CJ, Weaver SC. Rationally Attenuated Vaccines for Venezuelan Equine Encephalitis Protect Against Epidemic Strains with a Single Dose.. Vaccines (Basel) 2020 Sep 2;8(3).
    doi: 10.3390/vaccines8030497pubmed: 32887313google scholar: lookup
  13. Lundstrom K. Self-Amplifying RNA Viruses as RNA Vaccines.. Int J Mol Sci 2020 Jul 20;21(14).
    doi: 10.3390/ijms21145130pubmed: 32698494google scholar: lookup
  14. Stromberg ZR, Fischer W, Bradfute SB, Kubicek-Sutherland JZ, Hraber P. Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses.. Vaccines (Basel) 2020 Jun 3;8(2).
    doi: 10.3390/vaccines8020273pubmed: 32503232google scholar: lookup
  15. Adam L, Tchitchek N, Todorova B, Rosenbaum P, Joly C, Poux C, Chapon C, Spetz AL, Ustav M, Le Grand R, Martinon F. Innate Molecular and Cellular Signature in the Skin Preceding Long-Lasting T Cell Responses after Electroporated DNA Vaccination.. J Immunol 2020 Jun 15;204(12):3375-3388.
    doi: 10.4049/jimmunol.1900517pubmed: 32385135google scholar: lookup
  16. Suschak JJ, Dupuy LC, Shoemaker CJ, Six C, Kwilas SA, Spik KW, Williams JA, Schmaljohn CS. Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus.. Mol Ther Methods Clin Dev 2020 Jun 12;17:810-821.
    doi: 10.1016/j.omtm.2020.04.009pubmed: 32296729google scholar: lookup
  17. Gary EN, Weiner DB. DNA vaccines: prime time is now.. Curr Opin Immunol 2020 Aug;65:21-27.
    doi: 10.1016/j.coi.2020.01.006pubmed: 32259744google scholar: lookup
  18. Suschak JJ, Schmaljohn CS. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.. Hum Vaccin Immunother 2019;15(10):2359-2377.
    doi: 10.1080/21645515.2019.1651140pubmed: 31589088google scholar: lookup
  19. Wai CYY, Leung NYH, Leung PSC, Chu KH. Modulating Shrimp Tropomyosin-Mediated Allergy: Hypoallergen DNA Vaccines Induce Regulatory T Cells to Reduce Hypersensitivity in Mouse Model.. Int J Mol Sci 2019 Sep 19;20(18).
    doi: 10.3390/ijms20184656pubmed: 31546958google scholar: lookup
  20. Kwak JE, Kim YI, Park SJ, Yu MA, Kwon HI, Eo S, Kim TS, Seok J, Choi WS, Jeong JH, Lee H, Cho Y, Kwon JA, Jeong M, Maslow JN, Kim YE, Jeon H, Kim KK, Shin EC, Song MS, Jung JU, Choi YK, Park SH. Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets.. Nat Commun 2019 Aug 23;10(1):3836.
    doi: 10.1038/s41467-019-11815-4pubmed: 31444366google scholar: lookup
  21. Sharma A, Knollmann-Ritschel B. Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.. Viruses 2019 Feb 18;11(2).
    doi: 10.3390/v11020164pubmed: 30781656google scholar: lookup
  22. Samsa MM, Dupuy LC, Beard CW, Six CM, Schmaljohn CS, Mason PW, Geall AJ, Ulmer JB, Yu D. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.. Mol Ther 2019 Apr 10;27(4):850-865.
    doi: 10.1016/j.ymthe.2018.12.013pubmed: 30770173google scholar: lookup
  23. Phelps AL, O'Brien LM, Eastaugh LS, Davies C, Lever MS, Ennis J, Zeitlin L, Nunez A, Ulaeto DO. Aerosol infection of Balb/c mice with eastern equine encephalitis virus; susceptibility and lethality.. Virol J 2019 Jan 5;16(1):2.
    doi: 10.1186/s12985-018-1103-7pubmed: 30611287google scholar: lookup
  24. Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases.. Acta Biomater 2018 Oct 15;80:31-47.
    doi: 10.1016/j.actbio.2018.08.033pubmed: 30172933google scholar: lookup
  25. Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.. Hum Gene Ther 2018 Sep;29(9):1011-1028.
    doi: 10.1089/hum.2018.075pubmed: 30027768google scholar: lookup
  26. Dupuy LC, Richards MJ, Livingston BD, Hannaman D, Schmaljohn CS. A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.. J Immunol Res 2018;2018:8521060.
    doi: 10.1155/2018/8521060pubmed: 29967804google scholar: lookup
  27. Petkov S, Starodubova E, Latanova A, Kilpeläinen A, Latyshev O, Svirskis S, Wahren B, Chiodi F, Gordeychuk I, Isaguliants M. DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response.. PLoS One 2018;13(6):e0197902.
    doi: 10.1371/journal.pone.0197902pubmed: 29864114google scholar: lookup
  28. Dong LL, Tang R, Zhai YJ, Malla T, Hu K. DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.. Int J Ophthalmol 2017;10(11):1633-1639.
    doi: 10.18240/ijo.2017.11.01pubmed: 29181304google scholar: lookup
  29. Cashman KA, Wilkinson ER, Wollen SE, Shamblin JD, Zelko JM, Bearss JJ, Zeng X, Broderick KE, Schmaljohn CS. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.. Hum Vaccin Immunother 2017 Dec 2;13(12):3010-3019.
    doi: 10.1080/21645515.2017.1382780pubmed: 29135337google scholar: lookup
  30. Haidari G, Cope A, Miller A, Venables S, Yan C, Ridgers H, Reijonen K, Hannaman D, Spentzou A, Hayes P, Bouliotis G, Vogt A, Joseph S, Combadiere B, McCormack S, Shattock RJ. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.. Sci Rep 2017 Oct 12;7(1):13011.
    doi: 10.1038/s41598-017-13331-1pubmed: 29026141google scholar: lookup
  31. Bounds CE, Terry FE, Moise L, Hannaman D, Martin WD, De Groot AS, Suschak JJ, Dupuy LC, Schmaljohn CS. An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice.. Hum Vaccin Immunother 2017 Dec 2;13(12):2824-2836.
    doi: 10.1080/21645515.2017.1329788pubmed: 28575582google scholar: lookup
  32. Datta D, Bansal GP, Gerloff DL, Ellefsen B, Hannaman D, Kumar N. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.. Vaccine 2017 Jan 5;35(2):264-272.
    doi: 10.1016/j.vaccine.2016.11.072pubmed: 27912985google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.